Revelation Biosciences files neutral 8-K, attaches Q2 2025 press release

Rhea-AI Filing Summary

On 8 Aug 2025 Revelation Biosciences, Inc. (Nasdaq: REVB, REVBW) filed a Form 8-K to furnish, under Item 2.02, a press release announcing its financial results for the three and six months ended 30 Jun 2025. The press release itself is provided as Exhibit 99.1 but is not included in the body of the filing and is deemed “furnished,” not “filed,” under the Exchange Act, limiting liability and incorporation by reference. No revenue, EPS or balance-sheet figures appear within the 8-K text.

Aside from identifying the exhibit and reiterating the company’s security listings, the report discloses no strategic transactions, leadership changes or other material events. Consequently, the filing serves primarily as a procedural notice directing investors to the separate earnings release; market impact should be assessed only after reviewing that exhibit.

Insights

Financial Analyst

TL;DR: Procedural 8-K; no numbers disclosed—neutral until press release reviewed.

The company simply complies with SEC rules by furnishing its Q2 2025 earnings release. Because the actual financial metrics are absent, investors receive no new quantitative insight from this document alone. The impact is neutral; valuation implications depend entirely on the separate Exhibit 99.1 contents.

0001810560false0001810560revb:RedeemableWarrantsEachExercisableForA150400ThShareOfCommonStockAtAnExercisePriceOf579600PerShareMember2025-08-082025-08-0800018105602025-08-082025-08-080001810560us-gaap:CommonStockMember2025-08-082025-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 08, 2025

REVELATION BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39603	84-3898466
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4660 La Jolla Village Drive Suite 100
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 800-3717

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		REVB		The Nasdaq Stock Market LLC
Redeemable warrants, each exercisable for a 1/50,400th share of common stock at an exercise price of $579,600 per share		REVBW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2025, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1.

The information in Item 2.02 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated August 8, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		REVELATION BIOSCIENCES, INC.
Date: August 8, 2025	By:	/s/ Chester S. Zygmont, III
		Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)

FAQ

What did Revelation Biosciences (REVB) file on August 8 2025?

A Form 8-K furnishing a press release with Q2 2025 and six-month financial results.

Where can investors find REVB’s Q2 2025 financial figures?

The numbers are contained in Exhibit 99.1 to this 8-K, not in the main filing.

Does the 8-K include any material transactions or leadership changes?

No. The filing solely furnishes the earnings press release; no other events are disclosed.

Are the furnished results considered "filed" with the SEC?

No. Item 2.02 information is furnished, not filed, limiting Exchange Act liability.